FLT3 and acute myeloid leukemia: The lack of approved targeted drugs in patients with treatment-naïve AML harboring the FLT3 mutation and unsuitable for chemotherapy and the low efficacy of single-agent therapy with short remission times in patients with R/R AML have prompted the search for additional effective treatments.